Race against time: can starting cancer drug sooner save more lives?
NCT ID NCT05696782
Summary
This study is testing whether starting an immunotherapy drug called durvalumab sooner after finishing chemotherapy and radiation can better control stage III lung cancer. Researchers want to see if starting treatment within 14 days (instead of the usual longer wait) is safe, effective, and practical for patients. They'll also identify any barriers that might prevent patients from starting treatment quickly.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONSMALL CELL LUNG CANCER STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wake Forest Baptist Comprehensive Cancer Center
RECRUITINGWinston-Salem, North Carolina, 27157, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.